PT - JOURNAL ARTICLE AU - Bouton, Tara C. AU - Atarere, Joseph AU - Turcinovic, Jacquelyn AU - Seitz, Scott AU - Sher-Jan, Cole AU - Gilbert, Madison AU - White, Laura AU - Zhou, Zhenwei AU - Hossain, Mohammad M. AU - Overbeck, Victoria AU - Doucette-Stamm, Lynn AU - Platt, Judy AU - Landsberg, Hannah E. AU - Hamer, Davidson H. AU - Klapperich, Catherine AU - Jacobson, Karen R. AU - Connor, John H. TI - Viral dynamics of Omicron and Delta SARS-CoV-2 variants with implications for timing of release from isolation: a longitudinal cohort study AID - 10.1101/2022.04.04.22273429 DP - 2022 Jan 01 TA - medRxiv PG - 2022.04.04.22273429 4099 - http://medrxiv.org/content/early/2022/04/05/2022.04.04.22273429.short 4100 - http://medrxiv.org/content/early/2022/04/05/2022.04.04.22273429.full AB - Background In January 2022, United States guidelines shifted to recommend isolation for 5 days from symptom onset, followed by 5 days of mask wearing. However, viral dynamics and variant and vaccination impact on culture conversion are largely unknown.Methods We conducted a longitudinal study on a university campus, collecting daily anterior nasal swabs for at least 10 days for RT-PCR and culture, with antigen rapid diagnostic testing (RDT) on a subset. We compared culture positivity beyond day 5, time to culture conversion, and cycle threshold trend when calculated from diagnostic test, from symptom onset, by SARS-CoV-2 variant, and by vaccination status. We evaluated sensitivity and specificity of RDT on days 4-6 compared to culture.Results Among 92 SARS-CoV-2 RT-PCR positive participants, all completed the initial vaccine series, 17 (18.5%) were infected with Delta and 75 (81.5%) with Omicron. Seventeen percent of participants had positive cultures beyond day 5 from symptom onset with the latest on day 12. There was no difference in time to culture conversion by variant or vaccination status. For the 14 sub-study participants, sensitivity and specificity of RDT were 100% and 86% respectively.Conclusions The majority of our Delta- and Omicron-infected cohort culture-converted by day 6, with no further impact of booster vaccination on sterilization or cycle threshold decay. We found that rapid antigen testing may provide reassurance of lack of infectiousness, though masking for a full 10 days is necessary to prevent transmission from the 17% of individuals who remain culture positive after isolation.Main Point Beyond day 5, 17% of our Delta and Omicron-infected cohort were culture positive. We saw no significant impact of booster vaccination on within-host Omicron viral dynamics. Additionally, we found that rapid antigen testing may provide reassurance of lack of infectiousness.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Massachusetts Consortium on Pathogen Readiness (MassCPR) and Boston University. T.C.B., L.F.W., and Z.Z. are supported by the National Institute of Health (NIAID K23 grant AI152930-01A1and R35GM141821).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by both the Boston University Charles River Campus Institutional Review Board and the Boston University Medical Campus Institutional Review Board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.